NebiusNBIS

Business Snapshot

• Nebius Group N.V. Class A ordinary shares trade on NASDAQ under NBIS. The payload does not provide a sector, industry description, operating segments, or business guidance.
• NBIS is trading at $232.80 in pre-market trading. Over the available 200 daily bars, the stock rose from $95.02 to $232.80, a gain of approximately 145%, with a recorded high of $299.86 and low of $73.52.
• The financial profile is characterized by rapid changes in scale, substantial investment spending, and significant financing activity. The latest reported period shows $529.8 million of revenue, -$611.7 million of operating income, $82.5 million of net income, and -$3.681 billion of free cash flow.

Financial Trends

• Revenue: Revenue increased from $7.417 billion in 2022 to $8.921 billion in 2023 (+$1.504 billion, approximately +20.3%), then fell sharply to $117.5 million in 2024 (-$8.804 billion, approximately -98.7%). It recovered to $529.8 million in 2025 (+$412.3 million, approximately +351%), but remained approximately 92.9% below 2022. The trajectory is therefore a sharp contraction followed by recovery from a low base, not a return to the earlier revenue level.
• Operating margin: Operating margin declined from 2.54% in 2022 to 3.56% in 2023, then deteriorated to -375.06% in 2024 before improving to -115.46% in 2025. The latest margin improved by 259.60 percentage points versus 2024, but remains deeply negative and below 2022–2023 levels.
• Net margin: Net margin moved from 7.56% in 2022 to 2.48% in 2023, collapsed to -545.87% in 2024, and improved to 15.57% in 2025. The latest improvement reflects positive net income despite negative operating income; the payload does not provide the detailed drivers of that difference.
• Net income and EPS: Net income declined from $561.1 million in 2022 to $221.5 million in 2023, fell to -$641.4 million in 2024, and recovered to $82.5 million in 2025. Basic EPS followed the same pattern: $1.52, $0.60, -$2.28, and $0.34, respectively.
• Free cash flow: FCF deteriorated every period: -$125.8 million in 2022, -$227.2 million in 2023, -$562.1 million in 2024, and -$3.681 billion in 2025. Latest FCF worsened by $3.119 billion versus 2024 and by approximately $3.555 billion versus 2022. This is the clearest negative financial trend.
• Cash flow and capital expenditures: Cash from operations rose from $592.8 million in 2022 to $783.4 million in 2023, declined to $245.6 million in 2024, then recovered to $384.8 million in 2025. Capital expenditures increased from $718.6 million in 2022 to $1.011 billion in 2023, declined to $807.7 million in 2024, then surged to $4.066 billion in 2025. The 2025 FCF deterioration is therefore primarily associated with dramatically higher investment spending relative to operating cash generation.
• Cash and liquidity: Cash and equivalents were $288.5 million in 2022, $110.7 million in 2023, $2.435 billion in 2024, and $3.678 billion in 2025. Latest cash increased by $1.244 billion versus 2024 and by approximately $3.390 billion versus 2022.
• Balance-sheet scale: Total assets rose from $8.768 billion in 2022 to $8.755 billion in 2023, dropped to $3.549 billion in 2024, then surged to $12.431 billion in 2025. Total liabilities increased from $3.960 billion in 2022 to $5.461 billion in 2023, fell to $294.9 million in 2024, then jumped to $7.837 billion in 2025. Equity declined from $4.497 billion in 2022 to $3.294 billion in 2023, dipped slightly to $3.254 billion in 2024, and recovered to $4.594 billion in 2025.
• Debt: Long-term debt increased from $424.9 million in 2022 to $551.2 million in 2023, was not reported for 2024, and rose to $4.103 billion in 2025. Debt-to-equity moved from 0.09 in 2022 to 0.17 in 2023, was unavailable for 2024, and reached 0.89 in 2025. This represents materially higher leverage than two periods earlier.
• Working capital: Working capital was $740.6 million in 2022, fell to -$416.9 million in 2023, recovered to $2.269 billion in 2024, and increased to $3.184 billion in 2025. The current ratio improved from 0.89 in 2023 to 9.60 in 2024, then moderated to 3.08 in 2025, remaining above 1.0.

Financial Health

• The latest balance sheet has substantial liquidity: $3.678 billion of cash, $3.184 billion of working capital, and a 3.08 current ratio. These figures are stronger than in 2022–2023 and provide a visible liquidity buffer.
• However, the quality of that liquidity should be considered alongside the cash-flow trajectory. The company generated only $384.8 million from operations while spending $4.066 billion on capital expenditures, producing -$3.681 billion of FCF. Continued investment at this scale could require additional financing if operating cash flow does not expand materially.
• Financing cash flow was $5.126 billion in 2025, compared with $825.5 million in 2024 and $466.6 million in 2023. The sharp financing increase helped support the cash balance and investment program, but also coincided with long-term debt rising to $4.103 billion.
• Profitability remains mixed. Net income turned positive in 2025, but operating income remained -$611.7 million and operating margin remained -115.46%. The company has not yet demonstrated sustained positive operating profitability in the provided periods.
• Shares outstanding increased from 235.754 million in 2024 to 253.017 million in 2025, an increase of approximately 17.263 million shares, or 7.3%. This indicates some dilution over the latest period.
• Overall, the latest period shows stronger liquidity and revenue recovery, but also much heavier capital intensity, greater leverage, dilution, and deeply negative operating and free-cash-flow performance.

Insider Activity

• Insider sentiment is classified as Neutral (-10) for the stated period, but the transaction value is clearly skewed toward selling: $8.429 million of sales across 16 transactions, versus $0 of purchases across 10 transactions.
• Marc Boroditsky reported sales totaling approximately $6.999 million at prices from $197.00 to $250.00. John Wilson Boynton IV reported multiple sales on September 15 at prices ranging from $207.67 to $216.52, totaling approximately $1.339 million.
• Several September 1 entries are shown as purchases at $0, including transactions involving multiple insiders. These appear to be non-cash or grant-related entries in the supplied data rather than open-market purchases; they should not be treated as evidence of insider buying conviction.
• The available insider data therefore shows meaningful reported selling and no dollar-value purchases, a modest negative signal. It does not establish the reason for the sales or indicate whether they reflect scheduled transactions, compensation, tax obligations, or discretionary selling.

Multi-Timeframe Technical Context

• Ultra-short horizon — minutes: Only daily data is supplied, so there is no reliable 1-minute order-flow or intraday momentum analysis. The stock is in pre-market trading at $232.80, below the recorded session high of $299.86 and above the session low of $73.52. That extremely wide stated range implies elevated volatility, but the payload does not establish whether those values represent a normal session range, an event-related move, or a data anomaly.
• Short horizon — hours to days: Price is above the 12-day EMA ($221.08), 26-day EMA ($219.80), 50-day EMA ($217.17), 20-day SMA ($218.08), and 50-day SMA ($212.22). This preserves a bullish moving-average structure.
• The daily RSI-14 is 61.71 and RSI-21 is 54.01. Momentum is positive but not at an extreme overbought reading based on the supplied indicators.
• Daily MACD is positive at 1.2885 versus a 0.9010 signal line, supporting near-term upside momentum. Current volume of approximately 17.53 million is above the 20-day average of approximately 14.91 million, or about 17.7% higher.
• Price is near the upper Bollinger Band: $232.80 versus an upper band of $242.10, middle band of $218.08, and lower band of $194.06. This supports momentum but also leaves the stock vulnerable to mean reversion if it fails to clear the upper band.
• Long horizon — weeks to months: The stock remains well above its 200-day SMA of $161.39, and the 200-bar move is strongly positive. However, the distance from the 200-day average, the $15.41 ATR, the recorded $299.86 high, and the broad stated trading range all point to substantial volatility and elevated drawdown risk.
• Technical strength is currently stronger than the fundamental operating profile. The chart favors momentum continuation while price holds the $218–$221 moving-average cluster, but a break below that area would weaken the short-term trend.

Bull / Bear Cases

• Short-term bull case: Price holds above the $218–$221 EMA/SMA cluster, MACD remains above its signal line, volume stays above average, and the stock challenges the upper Bollinger Band near $242.10. A sustained move through that area could reopen the path toward the prior recorded high of $299.86.
• Short-term bear case: Failure near $242.10, combined with a loss of the $218–$221 support cluster, would suggest momentum exhaustion and raise the risk of a move toward the middle Bollinger Band at $218.08, then potentially the lower band at $194.06. The high ATR and large stated session range make downside moves potentially fast.
• Long-term bull case: Revenue recovered from $117.5 million to $529.8 million, cash increased to $3.678 billion, working capital improved to $3.184 billion, and operating cash flow recovered to $384.8 million. If the heavy investment program converts into substantially higher revenue and operating cash flow, the balance sheet may support further expansion.
• Long-term bear case: FCF worsened to -$3.681 billion, operating income remained negative at -$611.7 million, long-term debt rose to $4.103 billion, and shares outstanding increased by approximately 7.3% in the latest comparison. The company may need continued external funding if capital expenditures remain high and operating profitability does not improve.
• Key tension: The market trend is strongly bullish, but the supplied financial trend shows revenue still far below 2022, persistently negative operating profitability, sharply negative FCF, and higher leverage. The long-term thesis depends heavily on whether investment spending produces a significant improvement in operating scale and cash generation.

Key Levels & Triggers

…